Guibert J, Herman H, Capron M H
Hôpital Saint-Joseph, Paris.
Contracept Fertil Sex. 1997 Jan;25(1):79-84.
compare the acceptability of 3-day regimen with that of 10-day regimen of fluoroquinolones for the treatment of recurrent uncomplicated lower urinary tract infection in women.
a multicentric, randomized open trial was conduced in 421 patients by gynecologic and general practitioners to determine acceptability, efficacy and safety of lomefloxacin 400 mg in a once a day dose given for three days compared with norfloxacin 800 mg in twice a day dose given for ten days for the treatment of recurrent uncomplicated lower urinary tract infection in women.
acceptability, assessed at day 14, was significantly better for lomefloxacin group than norfloxacin group, respectively 57,1 p.100 and 38,0 p.100. Clinical success rate at day 14 was 97,2 p.100 for lomefloxacin and 97,5 p.100 for norfloxacin; at day 30 clinical success rate was respectively 97,6 p.100 and 98,1 p.100 relapse at one year was comparable between two groups. Adverse events were reported respectively in 15,6 p.100 and 16,6 p.100 of the patients, vaginal infections, dermatologic disorders and digestive disorders (abdominal pain, nausea) predominated. There were no serious adverse event.
the acceptability is better for a 3-day regimen of lomefloxacin than a 10-day regimen of norfloxacin for treatment of recurrent uncomplicated lower urinary tract infection in women for comparable efficacy and safety.
比较氟喹诺酮类药物3天疗程与10天疗程治疗女性复发性单纯性下尿路感染的可接受性。
由妇科和全科医生对421例患者进行多中心随机开放试验，以确定400毫克洛美沙星每日一次给药3天与800毫克诺氟沙星每日两次给药10天治疗女性复发性单纯性下尿路感染的可接受性、疗效和安全性。
在第14天评估的可接受性方面，洛美沙星组显著优于诺氟沙星组，分别为57.1%和38.0%。第14天的临床成功率，洛美沙星为97.2%，诺氟沙星为97.5%；第30天的临床成功率分别为97.6%和98.1%，两组一年复发率相当。分别有15.6%和16.6%的患者报告了不良事件，以阴道感染、皮肤疾病和消化系统疾病（腹痛、恶心）为主。无严重不良事件。
对于女性复发性单纯性下尿路感染，洛美沙星3天疗程在疗效和安全性相当的情况下，其可接受性优于诺氟沙星10天疗程。
